|Bid||50.41 x 800|
|Ask||50.42 x 1200|
|Day's Range||49.59 - 50.88|
|52 Week Range||38.48 - 61.71|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||14.44|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||1.60 (3.21%)|
|Ex-Dividend Date||May 12, 2022|
|1y Target Est||59.33|
The European health regulator on Thursday endorsed the use of AstraZeneca's COVID vaccine, Vaxzevria, as a booster. The recommendation, made by a committee of the European Medicines Agency (EMA), encompasses adults who have either been previously vaccinated by Vaxzevria or an mRNA vaccine, such as the ones made by Pfizer and BioNTech or Moderna. The recommendation comes weeks after the EMA backed the use of Pfizer-BioNTech's Comirnaty as a booster for adults who have previously been inoculated with other vaccines.
The U.S. National Institutes of Health is in talks with Pfizer Inc about studying whether a longer course of the drugmaker's COVID-19 antiviral treatment Paxlovid is needed to prevent reinfections, top U.S. infectious diseases expert Dr. Anthony Fauci said on Wednesday. "We're going to be planning what studies we're going to be doing relatively soon, within the next few days" in order to determine whether or not a longer course is needed, Fauci said during a White House COVID-19 briefing. Some patients have reported that COVID symptoms recurred after completing the five-day course of treatment and experiencing improvement, but exactly how many have experienced such a rebound is unclear.